论文部分内容阅读
目的探讨改良他汀序贯治疗急性冠脉综合症(ACS)患者的调脂疗效及其安全性。方法 107例确诊为ACS的住院患者,随机分为观察组(改良他汀序贯治疗组,57例)和对照组(口服阿托伐他汀20mg/d,50例)。检测入院24 h内、4周、8周早晨空腹血脂(包括血清总胆固醇(TC)、总甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C))、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、肌酸激酶(CK),观察药物不良反应。结果①与对照组比较,应用改良他汀序贯治疗的ACS患者血TC、LDL-C、TG水平均降低,具有统计学差异(P<0.05),HDL-C水平增高,具有统计学差异(P<0.05)。②与对照组比较,应用改良他汀序贯治疗的ACS患者血AST、ALT、CK水平无明显变化,两组药物不良反应轻微,统计学无显著性差异(P>0.05)。结论①改良他汀序贯治疗方案治疗ACS调脂效果确切;②改良他汀序贯方案治疗ACS安全性较好。
Objective To investigate the efficacy and safety of modified statin sequential therapy in patients with acute coronary syndrome (ACS). Methods A total of 107 inpatients diagnosed with ACS were randomly divided into observation group (modified statin group, 57 cases) and control group (oral atorvastatin 20 mg / d, 50 cases). The fasting blood lipids (including serum total cholesterol (TC), total triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL- C)), alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK), observed adverse drug reactions. Results ① Compared with the control group, the levels of TC, LDL-C and TG in serum of ACS patients treated with modified statin were significantly lower (P <0.05) and HDL-C levels were significantly higher (P <0.05). ②Compared with the control group, there was no significant change in serum AST, ALT and CK levels in the ACS patients treated with modified statin sequential therapy. There was no significant difference in adverse drug reactions between the two groups (P> 0.05). Conclusions ① The improved statin sequential therapy regimen has the exact effect on ACS lipid regulation; ② The modified statin sequential therapy is safe and safe.